Use of infliximab-daclizumab combination for the treatment of acute and chronic graft-versus-host disease of the liver and gut

Pediatric Blood and Cancer

Volumn 49, Issue 2, 2007, Pages 212-215

  Rodriguez, Vilmarie ^a   Anderson, Peter M ^a   Trotz, Barbara A ^a   Arndt, Carola A S ^a   Allen, Julia A ^a   Khan, Shakila P ^a  

^a MAYO CLINIC   (United States)

Author keywords

Daclizumab; Graft versus host disease; Immunosuppression; Infliximab

Indexed keywords

CYCLOPHOSPHAMIDE; DACLIZUMAB; ETOPOSIDE; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; MESNA; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BONE MARROW TRANSPLANTATION; CASE REPORT; CHILDHOOD LEUKEMIA; CHRONIC GRAFT VERSUS HOST DISEASE; COMBINATION CHEMOTHERAPY; CYTOMEGALOVIRUS INFECTION; DIARRHEA; DRUG WITHDRAWAL; GRAFT VERSUS HOST REACTION; HLA TYPING; HUMAN; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER TOXICITY; MALE; MULTIPLE CYCLE TREATMENT; MYELOMONOCYTIC LEUKEMIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; REPEATED DRUG DOSE; SCHOOL CHILD; TREATMENT OUTCOME;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHRONIC DISEASE; COMBINED MODALITY THERAPY; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GRAFT VS HOST DISEASE; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; INTESTINAL MUCOSA; LEUKEMIA, LYMPHOCYTIC, ACUTE, L2; LEUKEMIA, MYELOMONOCYTIC, CHRONIC; LIVER; MYCOPHENOLIC ACID; PREDNISONE; RECURRENCE; REMISSION INDUCTION; REOPERATION; TACROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34447280617     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.20648     Document Type: Article

References (20)

1. Bron D. Graft-versus-host disease. Curr Opin Oncol 1994;6:358-364.
2. Martin PJ, Schoch G, Fisher L, et al. A retrospective analysis of therapy for acute graft-versus-host disease: Secondary treatment. Blood 1991;77:1821-1828.
3. Hiscott A, McLellan DS. Graft-versus-host disease in allogeneic bone marrow transplantation: The role of monoclonal antibodies in prevention and treatment. Br J Biomed Sci 2000;57:163-169.
4. Krenger W, Hill GR, Ferrara JL. Cytokine cascades in acute graft-versus-host disease. Transplantation 1997;64:553-558.
5. Targan SR, Hanauer SB, van Deventer SJH, et al. Crohn's Disease cA2 Study Group. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor oc for Crohn's disease. N Engl J Med 1997;337:1029-1035.
6. Queen C, Schneider WP, Selick HE, et al. A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 1989;86:10029-10033.
7. Depper JM, Leonard WJ, Robb RJ, et al. Blockade of the interleukin-2 receptor by anti-Tac antibody: Inhibition of human lymphocyte activation. J Immunol 1983;131:690-696.
8. Hervé P, Flesch M, Tiberghien P, et al. Phase I-II trial of a monoclonal anti-tumor necrosis factor oc antibody for the treatment of refractory severe acute graft-versus-host disease. Blood 1992; 79:3362-3368.
9. Couriel D, Hicks K, Ippoliti C, et al. Infliximab for the treatment of graft-versus-host disease in allogeneic transplant recipients. Read at 36th annual meeting of the American Society of Clinical Oncology (ASCO), New Orleans, Louisiana, May 20 to 23, 2000.
10. Couriel D, Saliba R, Hicks K, et al. Tumor necrosis factor-α blockade for the treatment of acute GVHD. Blood 2004 Aug 1;104:649-654. Epub 2004 Apr 6.
11. Kobbe G, Schneider P, Rohr U, et al. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNα antibody. Bone Marrow Transplant 2001;28:47-49.
12. Jacobsohn DA, Hallick J, Anders V, et al. Infliximab for steroid-refractory acute GVHD: A case series. Am J Hematol 2003;74: 119-124.
13. Yamane T, Yamamura R, Aoyama Y, et al. Infliximab for the treatment of severe steroid refractory acute graft-versus-host disease in three patients after allogeneic hematopoietic transplantation. Leuk Lymphoma 2003;44:2095-2097.
14. Patriarca F, Sperotto A, Prosdocimo S, et al. Infliximab for the treatment of severe steroid-refractory acute graft-versus-host disease [abstract]. Blood 2003;102:451b.
15. Campos A, Vaz CP, Costa N, et al. Infliximab as salvage therapy for patients with acute graft-versus-host disease refractory to steroids [abstract]. Blood 2003;102:450b.
16. Bumgardner GL, Hardie I, Johnson RW, et al. Phase III Daclizumab Study Group. Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation. Transplantation 2001;72:839-845.
17. Adu D, Cockwell P, Ives NJ, et al. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. BMJ 2003;326:789.
18. Przepiorka D, Kernan NA, Ippoliti C, et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 2000;95:83-89.
19. Willenbacher W, Basara N, Blau IW, et al. Treatment of steroid refractory acute and chronic graft-versus-host disease with daclizumab. Br J Haematol 2001;112:820-823.
20. Srinivasan R, Chakrabarti S, Walsh T, et al. Improved survival in steroid-refractory acute graft versus host disease after non-myeloablative allogeneic transplantation using a daclizumab-based strategy with comprehensive infection prophylaxis. Br J Haematol 2004;124:777-786.